MDI Therapeutics

PAI-1 inhibition, anti-fibrotic therapeutics

modulatingsmall molecule

mditherapeutics.com·Detroit, Michigan, United States·

Plate C · C-HZUX

Projects

phase 1

drug program · high · Tue Nov 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of MDI-2517 in healthy participants after single and multiple dosing.

Phase 1 single-ascending-dose and multiple-ascending-dose clinical trials in healthy participants measuring safety, drug levels, and drug effects.

ClinicalTrials.gov record published for a SAD/MAD evaluation of MDI-2517 in healthy participants.

preclinical

drug program · high

Assess whether a novel PAI-1 inhibitor can provide pro-fibrinolytic and antithrombotic activity without prolonging bleeding time.

In vivo mouse electrolytic model of acute venous thrombosis comparing MDI-2268 doses, enoxaparin, and combination treatment against controls.

Publication of preclinical in vivo results for MDI-2268 in experimental venous thrombosis.

MDI-2268 reduced thrombus weight at tested doses and did not significantly affect bleeding time in the mouse model.

undisclosed

drug program · medium

Develop novel therapies for fibrosis and fibroproliferative diseases through inhibition of plasminogen activator inhibitor-1.

First-in-class orally available inhibitor of plasminogen activator inhibitor-1 based on University of Michigan enabling technologies.

Identified on company materials as MDI Therapeutics' lead program.

Loading section...

0-100 chain-logic scale · 15 dimensions · scored on public evidence